Effect of mometasone furoate nasal spray on quality of life of patients with acute rhinosinusitis.
This study evaluated the effect of mometasone furoate nasal spray (MFNS) on health-related quality of life (HRQoL) in patients with acute, uncomplicated rhinosinusitis. In a randomized, double-blind, placebo-controlled trial, HRQoL was assessed in 340 patients using the SinoNasal Outcome Test (SNOT)-20 questionnaire at baseline and after 15 days of treatment with MFNS 200 g once-daily (q.d.) or twice-daily (b.i.d.), amoxicillin 500 mg three times daily (t.i.d.), or placebo. Baseline mean total scores for SNOT-20 were similar in the four groups (2.15-2.23). At endpoint, there was a statistically significant improvement in mean total score only with MFNS 200 g b.i.d. (p = 0.047 versus placebo). MFNS was associated with numerical improvements in all SNOT-20 items compared with placebo. Treatment with MFNS 200 g b.i.d. is associated with a significant improvement in HRQoL compared with placebo in patients with acute, uncomplicated rhinosinusitis.
Bachert
Claus
C
Ear, Nose and Throat Department, University Hospital, Ghent, Belgium. claus.bachert@ugent.be
Meltzer
Eli O
EO
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D006305:Health Status Indicators; D006801:Humans; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000627:therapeutic use*; D011788:Quality of Life; D012220:Rhinitis / Q000188:drug therapy*; D012852:Sinusitis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate